-
1 Comment
Jiangsu Kanion Pharmaceutical Co.,Ltd is currently in a long term uptrend where the price is trading 5.8% above its 200 day moving average.
From a valuation standpoint, the stock is 82.3% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 1.7.
Jiangsu Kanion Pharmaceutical Co.,Ltd's total revenue sank by 34.4% to $724M since the same quarter in the previous year.
Its net income has dropped by 66.8% to $43M since the same quarter in the previous year.
Finally, its free cash flow fell by 68.1% to $50M since the same quarter in the previous year.
Based on the above factors, Jiangsu Kanion Pharmaceutical Co.,Ltd gets an overall score of 2/5.
| Exchange | SHG |
|---|---|
| CurrencyCode | CNY |
| ISIN | CNE000001CL7 |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Beta | 0.44 |
|---|---|
| Market Cap | 7B |
| PE Ratio | 21.3 |
| Target Price | 22.57 |
| Dividend Yield | None |
Jiangsu Kanion Pharmaceutical Co.,Ltd. researches and develops, produces, and sells Chinese medicines. It also offers medicines in the fields of anti-infections, orthopedics, gynecology, cardio and cerebrovascular, tonic-class, and others. In addition, the company provides herb extracts and formula granules, as well as OEM/ODM services. Jiangsu Kanion Pharmaceutical Co.,Ltd. was founded in 1975 and is based in Lianyungang, China.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 600557.SHG using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
